<DOC>
	<DOCNO>NCT02242461</DOCNO>
	<brief_summary>We hypothesize add-on Rhodiola L extract capsule regimen patient moderate-to-severe COPD ( 1 ) may provide potential systemic effect anti-inflammation anti-oxidation patient , effect ( 2 ) may reflect improvement patient ' physiological measurement , quality life exercise tolerance .</brief_summary>
	<brief_title>Rhodiola Crenulata Adjunctive Therapy COPD</brief_title>
	<detailed_description>This single center , randomize , double-blind , placebo control clinical trial . Eligibility criterion : 1. moderate-to-severe COPD patient 2. age 40-80 year , 3. abstain cigarette smoke maintain stable dose cigarette consumption , 4. acute exacerbation COPD , 5. clinically stable one month longer , 6. undergoing exercise training program . Primary endpoint : six-minute walk distance meter week 12 .</detailed_description>
	<criteria>1. moderatetosevere COPD patient 2. aged 4080 year , 3. abstain cigarette smoke maintain stable dose cigarette consumption , 4. acute exacerbation COPD , 5. clinically stable one month longer , 6. undergoing exercise training program . 1. uncontrolled diabetes mellitus plasma fasting sugar &gt; 200 mg/dl , 2. uremia CKD stage 5 , 3. chronic heart failureby NYFC III , 4. cerebrovascular disease , 5. uncontrolled anemia Hb &lt; 10 mg/dl , 6. active malignant disease , 7. hospitalize acute illness , 8. systemic prednisolone &gt; 10 mg per day .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>COPD , Rhodiola L. , clinical trial , biomarkers , spirometry</keyword>
</DOC>